Latest Capital Raises News

I Synergy Group Limited has successfully completed a $100,000 private placement at a 16.67% discount, aiming to bolster its growth and working capital. The move signals investor confidence as the technology company advances its digital solutions agenda.

Neurizon Therapeutics reports encouraging 8-month interim results for its ALS drug NUZ-001, secures Orphan Medicinal Product Designation in Europe, and raises $885,000 through a share placement, maintaining a robust $14 million cash position.

Terra Metals has secured an option to acquire a large tenement package adjacent to its flagship Dante Project, significantly expanding its exploration potential in Western Australia's West Musgrave region.

Nelson Resources bolstered its balance sheet with a $2.3 million placement and appointed Dr Louis Bucci as Executive Director, setting the stage for renewed exploration at its Fortnum and Yarri gold projects in early 2025.

Waratah Minerals Limited reported a $2.01 million net cash outflow from operating activities in the December 2024 quarter, ending with $4.23 million in cash and equivalents. The company continues its exploration efforts but faces notable cash burn that may pressure future funding.

CurveBeam AI has reported a record quarter for HiRise™ device purchase orders, driven by a strategic expansion with Stryker in Australia and New Zealand. The company also advanced its FDA regulatory pathway for its BMD module, setting sights on mid-2025 submission.

AUCyber Limited has recommended shareholders accept an increased cash takeover offer from 5G Networks Limited, raising the bid by 22.7% to 13.5 cents per share amid ongoing financial uncertainties.

Actinogen Medical accelerates recruitment in its pivotal XanaMIA Alzheimer's trial while securing a strong cash position of $22.9 million, underpinning its late-stage development and commercial readiness.

Agrimin Limited's latest quarterly cash flow report reveals a significant reduction in cash reserves alongside ongoing operational expenditures, prompting plans for further capital raising to maintain project momentum.

Syntara Limited has reported encouraging interim Phase 2 trial results for its lead drug candidate SNT-5505 in myelofibrosis, alongside a successful A$15 million capital raise to advance multiple clinical programs.

Vinyl Group Ltd delivered a standout Q2 FY25 with a 172% jump in cash receipts and strategic acquisitions poised to boost earnings. The company’s international expansion and debt reduction efforts signal a transformative phase ahead.

Syntara Limited reported a robust $11.35 million increase in cash during the December 2024 quarter, underpinned by government grants and steady operational inflows. The company closes the period with a strong cash position of $18.07 million, signaling financial resilience.